THE LONG VIEW

Bottom Line Up Front: China’s rapidly expanding brain-computer interface (BCI) clinical translation pipeline—marked by a surge in trials, regulatory approvals, and geographic concentration of expertise—poses a strategic challenge to Western leadership in neurotechnology, with implications for medical innovation, data security, and dual-use applications. Threat Identification: China has established a robust BCI translational ecosystem, integrating investigator-initiated trials (IITs), registered clinical trials, and regulatory-approved products. As of June 2026, 134 clinical trials were registered in the Chinese Clinical Trial Registry (ChiCTR), with 26 IITs and five BCI products approved by the National Medical Products Administration (NMPA) [Chen et al., 2026]. Notably, this includes the world’s first semi-invasive implantable BCI and an invasive closed-loop deep brain stimulation system with real-time neural recording—technologies that represent significant leaps in neural interface capabilities [Chen et al., 2026]. Probability Assessment: The growth trajectory is already evident, with BCI clinical trial registration increasing sharply since 2020 and research concentrated in high-capacity regions such as Guangdong, Shanghai, and Jiangsu [Chen et al., 2026]. The likelihood of China maintaining or accelerating this pace over the next 5–10 years is high, given sustained state support, centralized regulatory coordination, and integration across academic, clinical, and industrial sectors. Impact Analysis: The consequences are multifaceted. Clinically, China may achieve first-mover advantages in neurorehabilitation technologies, particularly for stroke recovery (the leading indication in 65.0% of trials) [Chen et al., 2026]. Economically, early market dominance could shift global supply chains and IP control. From a national security perspective, the dual-use potential of real-time neural data collection and decoding systems raises concerns about cognitive data exploitation, especially given the lack of transparent data governance frameworks. Furthermore, the predominance of non-invasive EEG-based systems (79.1% of studies) enables scalable deployment and vast neural dataset aggregation, potentially accelerating AI-driven algorithm development outside Western oversight [Chen et al., 2026]. Recommended Actions: 1) Expand monitoring of China’s BCI regulatory and clinical trial pipelines through open-source intelligence; 2) Accelerate U.S. and EU regulatory pathways for implantable and closed-loop BCI systems; 3) Invest in secure, interoperable neural data standards with strong privacy safeguards; 4) Strengthen export controls on critical neurotechnology components; 5) Foster public-private partnerships to bridge the ‘valley of death’ in BCI commercialization. Confidence Matrix: - Clinical trial growth: High confidence (based on ChiCTR data) [Chen et al., 2026] - Regulatory milestones: High confidence (NMPA approvals documented) [Chen et al., 2026] - Dual-use risk: Medium to high confidence (inferred from technical capabilities and data access) - Long-term dominance potential: Medium confidence (dependent on resolution of technical barriers like implant stability) [Chen et al., 2026]